Show simple item record

dc.contributor.authorNorata, Giuseppe
dc.contributor.authorTsimikas, S.
dc.contributor.authorPirillo, A.
dc.contributor.authorCatapano, A.
dc.identifier.citationNorata, G. and Tsimikas, S. and Pirillo, A. and Catapano, A. 2015. Apolipoprotein C-III: From Pathophysiology to Pharmacology. Trends in Pharmacological Sciences. 36 (10): pp. 675-687.

© 2015 Elsevier Ltd. All rights reserved. Apolipoprotein C-III (apoC-III) has a critical role in the metabolism of triglyceride (TG)-rich lipoproteins (TRLs). Animal models lacking the APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 leads to increased TG levels. In humans, loss-of-function mutations in APOC3 are associated with reduced plasma TG levels and reduced risk for ischemic vascular disease and coronary heart disease. Several hypolipidemic agents have been shown to reduce apoC-III, including fibrates and statins, and antisense technology aimed at inhibiting APOC3 mRNA to decrease the production of apoC-III is currently in Phase III of clinical development. Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders.

dc.titleApolipoprotein C-III: From Pathophysiology to Pharmacology
dc.typeJournal Article
dcterms.source.titleTrends in Pharmacological Sciences
curtin.departmentSchool of Biomedical Sciences
curtin.accessStatusFulltext not available

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record